Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Forsteo ® (teriparatide)
Forsteo® (teriparatide): Clinical Tests During Treatment
The Forsteo Summary of Product Characteristics does not specify laboratory tests to monitor; however, available literature offers suggestions on clinical work up during therapy.
Follow up tests to teriparatide therapy that may be utilized include1
total serum calcium
If symptoms such as nausea, vomiting, constipation, lower energy, or muscle weakness arise, as these may be signs of high blood calcium
LS and TH BMD by DXA after 24 months of therapy.1
1. Miller PD, Bilezikian JP, Deal C, et al. Clinical use of teriparatide in the real world: initial insights. Endocr Pract. 2004;10(2):139-148. http://dx.doi.org/10.4158/EP.10.2.139
BMD = bone mineral density
DXA = dual-energy x-ray absorptiometry
LS = lumbar spine
TH = total hip
Date of Last Review: January 21, 2020